| rivaroxaban / Generic mfg. |
NCT06476301: Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves |
|
|
| Not yet recruiting | 4 | 250 | NA | Rivaroxaban | RenJi Hospital | Anticoagulation | 02/26 | 12/26 | | |
NCT05671276: Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion |
|
|
| Recruiting | 4 | 150 | RoW | aspirin and clopidogrel, Rivaroxaban | The First Affiliated Hospital with Nanjing Medical University, Second Affiliated Hospital of Nantong University, Jiangsu Taizhou People's Hospital | Atrial Fibrillation, Left Atrial Appendage Occlusion, Silent Cerebral Embolism | 09/24 | 09/24 | | |
| Not yet recruiting | 4 | 1148 | NA | Apixaban, AVK, rivaroxaban, dabigatran, Aspirin | Assistance Publique - Hôpitaux de Paris | Stroke, Ischemic Stroke, Cerebral Infarction, Atrial Fibrillation | 09/25 | 03/28 | | |
NCT04135677: Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO |
|
|
| Recruiting | 4 | 826 | RoW | Rivaroxaban, new oral anticoagulation, DAPT, dual antiplatelet therapy | Shanghai Zhongshan Hospital | Left Atrial Appendage Thrombosis, Thrombi, Stroke | 10/24 | 10/24 | | |
SPIRIT, NCT05797376: Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation |
|
|
| Recruiting | 4 | 92 | RoW | Rivaroxaban 2.5mg, Xarelto 2.5mg | Asan Medical Center, Bayer | Atherosclerosis of Artery, Coronary Artery Disease, Peripheral Arterial Disease, Carotid Stenosis | 12/24 | 06/25 | | |
ChiCTR2300070526: Randomized controlled clinical study on the effect of early oral rivaroxaban on the prognosis of patients with acute ST-segment elevation myocardial infarction undergoing emergency PCI |
|
|
| Not yet recruiting | 4 | 1000 | | Rivaroxaban (5 mg St / 10 mg st) + aspirin 300 mg + clopidogrel bisulfate 300 mg or ticagrelor 180 mg ;Placebo + aspirin 300 mg + clopidogrel bisulfate 300 mg or ticagrelor 180 mg | Yueyang Central Hospital; Yueyang Central Hospital, Self-raised | Acute | | | | |
NCT05643651: Rivaroxaban for Children With Giant Coronary Artery Aneurysms After Kawasaki Disease |
|
|
| Not yet recruiting | 4 | 100 | RoW | Rivaroxaban Oral Tablet [Xarelto], Xarelto, Aspirin or Clopidogrel, Antiplatelet therapy, Warfarin, Vitamin K Antagonist | Children's Hospital of Fudan University | Kawasaki Disease, Coronary Artery Aneurysm | 09/25 | 03/26 | | |
NCT05009862: The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease |
|
|
| Recruiting | 4 | 75 | US | Rivaroxaban 2.5 Mg Oral Tablet, Placebo, Aspirin 81Mg Ec Tab | Vanderbilt University Medical Center, National Heart, Lung, and Blood Institute (NHLBI) | Peripheral Arterial Disease | 03/25 | 03/25 | | |
ChiCTR2300069986: Effect of oral dronedarone hydrochloride tablets on rivaroxaban serum concentration in patients with paroxysmal and persistent atrial fibrillation：A randomized, controlled, single-center clinical study |
|
|
| Not yet recruiting | 4 | 60 | | Dronedarone 400mg bid, Rivaroxaban 15mg qd, 1 month ;Rivaroxaban 15mg qd, 1 month | The Second Affiliated Hospital of the Military Medical University of the PLA Air Force; The Second Affiliated Hospital of the Military Medical University of the PLA Air Force, The CSPC Ouyi Pharmaceutical Co.，Ltd | Atrial Fibrillation | | | | |
IMPACT AF-PCI, NCT06103266: Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention |
|
|
| Not yet recruiting | 4 | 50 | NA | Rivaroxaban | J.P.S Henriques | Atrial Fibrillation, Coronary Artery Disease | 06/25 | 12/25 | | |
ChiCTR2100046712: Randomized controlled study of different antithrombotic strategies after occlusion of left atrial appendage with LACbes occluder |
|
|
| Recruiting | 4 | 296 | | dual antiplatelet (aspirin+ticagrelor) ;Rivaroxaban | Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Funding of Shanghai Hospital Develpment Center and self-financed | Atrial Fibrillation | | | | |
OCEAN, NCT02168829: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial |
|
|
| Active, not recruiting | 4 | 1284 | Europe, Canada, RoW | Rivaroxaban, Xarelto, Acetylsalicylic acid, Aspirin, ASA | Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Bayer, Biotronik Canada Inc | Atrial Fibrillation, Stroke | 07/25 | 08/25 | | |
PEPPER, NCT02810704: Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement |
|
|
| Recruiting | 4 | 20000 | Canada, US | Enteric Coated Aspirin, Aspirin, Warfarin, Coumadin, Rivaroxaban, Xarelto | Dartmouth-Hitchcock Medical Center, Patient-Centered Outcomes Research Institute, University of Maryland, Baltimore, Brigham and Women's Hospital, Northwestern University, Medical University of South Carolina | Pulmonary Embolism, Venous Thrombosis | 07/25 | 07/25 | | |
NCT06013020: Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus |
|
|
| Recruiting | 4 | 374 | RoW | NOAC+DAPT, Rivaroxaban + ticagrelor or clopidogrel + aspirin, DAPT, Ticagrelor or clopidogrel + aspirin | Zunyi Medical College | STEMI - ST Elevation Myocardial Infarction | 12/26 | 12/27 | | |
COBRRA AF, NCT04642430: COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation |
|
|
| Recruiting | 4 | 3018 | Canada | Apixaban, Eliquis, Rivaroxaban, Xarelto | Ottawa Hospital Research Institute, Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Institutes of Health Research (CIHR) | Atrial Fibrillation | 12/25 | 12/26 | | |
ChiCTR2200062238: Study on the efficacy and safety of prophylactic anticoagulation therapy in high-risk heart failure patients |
|
|
| Not yet recruiting | 4 | 602 | | Rivaroxaban 2.5mg bid ;None | China-Japan Union Hospital of Jilin University; China-Japan Union Hospital of Jilin University, The mechanism of Activin A in regulating abnormal differentiation of JAK2V617F mutant stem cells and promoting myocardial fibrosis | heart failure | | | | |
ChiCTR2300074934: Effect of pharmacogenetic polymorphisms on the pharmacokinetics and pharmacodynamics of rivaroxaban in elderly patients with non-valvular atrial fibrillation |
|
|
| Not yet recruiting | 4 | 200 | | none | Jinhua Municipal Central Hospital; Jinhua Municipal Central Hospital, Jinhua Central Hospital Youth Research Foundation (Grant NO: JY2022-2-03) | atrial fibrillation | | | | |
DaRe2THINK, NCT04700826: Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation |
|
|
| Recruiting | 4 | 3000 | Europe | Direct Oral Anticoagulants, apixaban, dabigatran, edoxaban or rivaroxaban | University of Birmingham, Clinical Practice Research Datalink, University Hospital Birmingham NHS Foundation Trust, University of Oxford, London School of Economics and Political Science, Aston University | Atrial Fibrillation | 01/26 | 01/31 | | |
| Recruiting | 4 | 250 | US | Bromocriptine, Parlodel, Cycloset, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Xarelto, Second Placebo | Dennis M. McNamara, MD, MS, National Heart, Lung, and Blood Institute (NHLBI) | Peripartum Cardiomyopathy, Postpartum | 06/26 | 12/28 | | |
ChiCTR2300074296: Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after thoracoscopic surgery for lung cancer: an open-label, multicenter, randomized, controlled trial |
|
|
| Not yet recruiting | 4 | 540 | | Oral rivaroxaban prolongs prophylactic anticoagulation ;none | Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, Scientific research fund | Venous Thromboembolism | | | | |
| Recruiting | 4 | 6660 | Europe | Dalteparin Sodium, Tinzaparin Sodium, Enoxaparin Sodium, Rivaroxaban, Apixaban, Dabigatran Etexilate | Imperial College London | Venous Thromboembolism, Varicose Veins | 06/26 | 12/26 | | |
ASPIRE-AF, NCT03968393: Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery |
|
|
| Recruiting | 4 | 2270 | Europe, Canada, RoW | Non-vitamin K oral anticoagulant (NOAC), Apixaban, Dabigatran, Edoxaban, Rivaroxaban | Population Health Research Institute, Hamilton Health Sciences Corporation | Stroke, Atrial Fibrillation | 12/26 | 12/28 | | |
NCT05638867: NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI |
|
|
| Recruiting | 4 | 3944 | RoW | Aspirin + Clopidogrel + Rivaroxaban, Triple Antithrombotic Therapy, Aspirin + Clopidogrel, Dual Antiplatelet Therapy | China National Center for Cardiovascular Diseases | Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome | 12/26 | 01/27 | | |
NCT06108414: Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation |
|
|
| Not yet recruiting | 4 | 4374 | NA | low-dose rivaroxaban, Standard-dose rivaroxaban | China National Center for Cardiovascular Diseases | Atrial Fibrillation, Anticoagulant Adverse Reaction, Stroke, Major Adverse Cardiac Events | 12/26 | 12/27 | | |
DANNOAC-VTE, NCT03129555: The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism |
|
|
| Recruiting | 4 | 5000 | Europe | Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet, Apixaban Oral Tablet | Herlev and Gentofte Hospital, Danish Society of Cardiology | Deep Vein Thrombosis, Pulmonary Embolism | 03/27 | 03/29 | | |
SHORT RUN AF, NCT05487950: Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk |
|
|
| Not yet recruiting | 4 | 550 | NA | Rivaroxaban group | Assistance Publique - Hôpitaux de Paris | Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA) | 04/27 | 04/27 | | |
DANNOAC-AF, NCT03129490: The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation |
|
|
| Recruiting | 4 | 11000 | Europe | Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet, Apixaban Oral Tablet | Herlev and Gentofte Hospital, Danish Society of Cardiology | Atrial Fibrillation, Atrial Flutter | 10/27 | 10/27 | | |
2015-001190-40: Etude prospective, randomisée, multicentrique des effets de l'administration du XARELTO ® (Rivaroxaban) au cours de la thrombose portale chronique. |
|
|
| Not yet recruiting | 3/4 | 296 | Europe | XARELTO, Tablet, XARELTO | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Thrombose portale chronique | | | | |
2012-005589-37: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism |
|
|
| Ongoing | 3 | 530 | Europe | Dalteparin sodium, Rivaroxaban, Dalteparin, Xarelto, Dalteparin, Xarelto | University of Warwick, Bayer plc | Venous Thromboembolism and Cancer | | | | |
2016-000958-36: RIDTS Study - Rivaroxaban for the treatment of symptomatic Isolated Distal deep vein Thrombosis Studio RIDTS- Rivaroxaban per il trattamento delle trombosi profonde distali isolate sintomatiche |
|
|
| Ongoing | 3 | 1100 | Europe | RIVAROXABAN, [BAY 59-7939], Film-coated tablet, Xarelto 15 mg, Xarelto 20 mg | DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE, Bayer | SYMPTOMATIC ISOLATED DISTAL DEEP VEIN THROMBOSIS Trombosi Venose Distali Isolate sintomatiche, SYMPTOMATIC ISOLATED DISTAL DEEP VEIN THROMBOSIS Trombosi Venose Distali Isolate sintomatiche, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR-IIR-16008226: Effectiveness of four different strategies of preoperative using rivaroxaban in patients undergoing fast-tract total knee arthroplasty |
|
|
| Recruiting | 3 | 240 | | rivaroxaban application, 1 Week, qd ;rivaroxaban application, 2 Week, qd ;rivaroxaban application, 3 Week, qd ;rivaroxaban application, 35 Day, qd | West China Hospital, Sichuan University; West China Hospital, Sichuan University, New Technology fund of West China Hospital Sichuan University | end-staged joint diseases | | | | |
| Not yet recruiting | 3 | 800 | Europe | Eliquis, Xarelto, Lixiana, Pradaxa, Warfarin, Sinthrome, Phenindione, Film-coated tablet, Capsule, hard, Tablet, Eliquis, Xarelto, Lixiana, Pradaxa, Warfarin, Sinthrome, Phenindione | University of Edinburgh, Chest Heart & Stroke Scotland, Medical Research Council | Spontaneous Intracranial Haemorrhage (ICH), Brain Haemorrhage, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2017-002433-31: REduced dose versus full-dose of direct oral anticoagulant after uNprOvoked Venous thromboEmbolism. |
|
|
| Ongoing | 3 | 2200 | Europe | APIXABAN, RIVAROXABAN, Capsule, ELIQUIS 5 mg, XARELTO 20 mg, ELIQUIS 2.5 mg, XARELTO 10 mg | CHRU de BREST, Health ministry | Patients with indications for long-term anticoagulation after VTE (i.e.; symptomatic PE or proximal DVT) initially treated during 6 to 12 months with anticoagulant therapy, venous thrombosis, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR-IIR-17011109: A prospective study of rivaroxaban in the prevention of PICC related thrombosis in cancer patients |
|
|
| Not yet recruiting | 3 | 300 | | Rivaroxaban+ conventional nursing ;Conventional nursing | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, The research was supported by Bayer Healthcare | Venous thromboembolism | | | | |
2015-005090-20: A comparison between rivaroxaban and placebo for the prevention of deep vein thrombosis or pulmonary embolism afetr laparoscpic surgery for colorectal cancer after initial heparin prophylaxis Confronto tra rivaroxaban e placebo per la prevenzione della trombosi venosa profonda e dell'embolia polmonare dopo chirurgia laparoscopica per neoplasia del colon e/o retto dopo la terapia iniziale con eparina |
|
|
| Ongoing | 3 | 646 | Europe | Rivaroxaban, [NA], Film-coated tablet, XARELTO - 10 MG COMPRESSE RIVESTITE CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) 30 COMPRESSE | FONDAZIONE FADOI, Bayer-Italia | Prevention of venous thromboembolism after laparoscopic surgery for colorectal cancer Prevenzione del tromboembolismo venoso dopo chirurgia laparoscopica per neoplasia del colon-retto, Prevention of venous thrombosis and pulmonary embolism after laparoscopic surgery for colorectal cancer Prevenzione della trombosi venosa e dell'embolia, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Not yet recruiting | 3 | 308 | US | apixaban, Eliquis, rivaroxaban, Xarelto | Indiana University, Indiana University Health | Venous Thromboembolism | 12/18 | 05/19 | | |
2018-003621-28: Short-term blood-thinning medication versus antiplatelet therapy for the prevention of blood clots following left atrial appendage closure. Tratamiento anticoagulante versus antiagregante durante un corto periodo de tiempo tras el cierre de orejuela izquierda para prevenir la formación de trombos en el dispositivo. |
|
|
| Not yet recruiting | 3 | 350 | Europe | Coated tablet, Capsule, hard, Clopidogrel, Aspirin, Rivaroxaban, Dabigatran, Apixaban, Edoxaban | IUCPQ, IUCPQ | Device thrombosis at 2 months and 12 months after left atrial appendage closure (LAAC)Ischemic events (stroke, TIA) at 2-month and 1-, 2-, 3-, 4-and 5-year follow-upBleeding events at 2-month and 1-, 2-, 3-, 4-and 5-year follow-up Trombosis del dispositivo evaluada por ecocardiografía transesofágica 2 meses y 12 meses tras el procedimiento. Eventos isquémicos (ictus, AIT) a los 2 meses y a 1-,2-,3-,4-,5- años de seguimientoEventos hemorrágicos a los 2 meses y a 1-,2-,3-,4-,5- años de seguimiento, Blood clots on the device at 2 months and 12-month after the procedure (left atrial appendage closure)Risk of cerebrovascular accident or bleeding at 2-month and 1-, 2-, 3-, 4-and 5-year follow-up Trombos en el dispositivo a los 2 y 12 meses tras el procedimiento (cierre de orejuela izquierda)Riesgo de ictus o hemorragia cerebral a los 2 meses y a 1-,2-,3-,4- y 5- años de seguimiento, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2021-001534-19: Direct oral Anticoagulants for Prevention of lEft ventRIcular Thrombus after anterior acute myocardial InFarction Impact de la prescription d’un traitement anticoagulant oral direct chez les patients pris en charge pour un infarctus du myocarde antérieur pour prévenir la formation d’un thrombus intra ventriculaire gauche |
|
|
| Not yet recruiting | 3 | 560 | Europe | Rivaroxaban 2,5 mg, Coated tablet, XARELTO 2,5 mg | AP-HP/DRCI, AP-HP/DRCI | Left ventricular (LV) thrombus after acute myocardial infarction (AMI) Thrombus intra ventriculaire gauche (VG) après un infarctus du myocarde (IDM), Anterior AMI patients Patients pris en charge pour un IDM antérieur, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-004652-15: AVAJAK: Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myelo-proliferative neoplasms AVAJAK: Apixaban/rivaroxaban Versus Aspirine en prévention primaire des complications thromboemboliques des néoplasies myéloprolifératives mutées pour JAK2V617F |
|
|
| Not yet recruiting | 3 | 1340 | Europe | Tablet, Gastro-resistant capsule, Eliquis, Xarelto, Aspirine Protec | CHRU de Brest, PHRC-K | Myelo-proliferative neoplasms including essential thrombocythemia, Polycythemia Vera, Prefibrotic myelofibrosis Néoplasies myéloprolifératives incluant les thrombocytémies essentielles, polyglobulies de Vaquez et pyélofibroses préfibrotiques, Myelo-proliferative neoplasms including essential thrombocythemia, Polycythemia Vera, Prefibrotic myelofibrosis Néoplasies myéloprolifératives incluant les thrombocytémies essentielles, polyglobulies de Vaquez et pyélofibroses préfibrotiques, Diseases [C] - Cancer [C04] | | | | |
2021-001554-61: Comparing effectiveness and safety of different blood thinners after transcatheter treatment for aortic stenosis |
|
|
| Not yet recruiting | 3 | 360 | Europe | Albyl-E, Eliquis, Xarelto, Lixiana, Tablet, acetylsalicylic acid, apixaban, rivaroxaban, edoxaban | Oslo University Hospital, not yet specified, application due | Patients with aortic stenosis undergoing transcatheter aortic valve implantation., Narrowing of the heart valve between the heart and the large blood vessel, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT03786757: Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT â…¡) |
|
|
| Not yet recruiting | 3 | 200 | RoW | Rivaroxaban, Xarelto® | RenJi Hospital | ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus | 03/22 | 12/22 | | |
| Recruiting | 3 | 280 | RoW | Rivaroxaban, Vitamin K Antagonist | RenJi Hospital, Shanghai 6th People's Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Minhang Central Hospital, Shanghai Songjiang Central Hospital, Shanghai Fengxian District Central Hospital, Zhoushan Hospital in Zhejiang Province | ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus | 03/22 | 12/23 | | |
| Completed | 3 | 6667 | Canada, RoW | Colchicine, Interferon-Beta, Aspirin, Rivaroxaban | Population Health Research Institute, Bayer | Coronavirus, Severe Acute Respiratory Syndrome | 12/22 | 12/22 | | |
REWARF-STEMI, NCT05705089: Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI |
|
|
| Completed | 3 | 50 | RoW | Rivaroxaban 15 MG, XARELTO, Warfarin | Rajaie Cardiovascular Medical and Research Center, Tehran Heart Center | Left Ventricular Thrombus, ST Segment Elevation Myocardial Infarction | 02/23 | 04/23 | | |
NCT04967573: Prophylactic vs Therapeutic Anticoagulation in Symptomatic Isolated Distal Deep Vein Thrombosis |
|
|
| Recruiting | 3 | 480 | RoW | Rivaroxaban | Shanghai Zhongshan Hospital | Venous Thrombosis | 06/23 | 12/23 | | |
NCT04891861: Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage |
|
|
| Not yet recruiting | 3 | 100 | NA | Apixaban, Rivaroxaban, Edoxaban, Dabigatran | University of Texas at Austin, University of Kansas | Anticoagulants; Increased | 07/23 | 07/23 | | |
NCT04142125: Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease |
|
|
| Completed | 3 | 101 | Canada | Rivaroxaban 2.5 Mg Oral Tablet bid, Xarelto, Acetylsalicyclic acid 81 mg tablet qd, Aspirin | Population Health Research Institute | Ischemic Stroke, Intracranial Atherosclerotic Disease | 09/23 | 09/23 | | |
NCT03702582: Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation |
|
|
| Completed | 3 | 100 | US | Rivaroxaban, Xarelto, Database of Molecules (PubChem CID): 6433119, Warfarin, Coumadin, Database of Molecules (PubChem CID): 54678486 | Massachusetts General Hospital | Atrial Fibrillation, Stroke, Bleeding | 10/23 | 10/23 | | |
CAPITALPCIAF, NCT03331484: The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention |
|
|
| Active, not recruiting | 3 | 40 | Canada | Ticagrelor, Rivaroxaban | Ottawa Heart Institute Research Corporation | Atrial Fibrillation, Acute Coronary Syndrome | 11/23 | 12/23 | | |
APERITIF, NCT05077683: Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - |
|
|
| Active, not recruiting | 3 | 560 | Europe | Rivaroxaban 2.5 MG [Xarelto], DAPT strategy | Assistance Publique - Hôpitaux de Paris | Myocardial Infarction, Acute, Left Ventricular Thrombus | 12/23 | 12/24 | | |
CARD-AXA, NCT05410275: Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients |
|
|
| Not yet recruiting | 3 | 10 | NA | Rivaroxaban | University Hospital, Tours | Chronic Hemodialysis Patients | 12/23 | 01/24 | | |
| Not yet recruiting | 3 | 10044 | NA | Rivaroxaban, Apixaban, Enoxaparin Injectable Solution, Tinzaparin Injectable Solution, Dalteparin Injectable Solution, Fondaparinux Injectable Product | Queen Mary University of London | Thrombosis, Injury Leg | 02/28 | 02/28 | | |
| Completed | 3 | 319 | Europe | Apixaban Oral Tablet, Eliquis, Dabigatran, Pradaxa, Edoxaban Tablets, Lixiana, Savaysa, Rivaroxaban, Xarelto | Imperial College London, Wuerzburg University Hospital, Julius-Maximilians University, Medical University of Graz, University of Liverpool, King's College London, Hospital Universitari Vall d'Hebron Research Institute, University of Bordeaux, Azienda Ospedaliera di Perugia, Aalborg University, STROKE ALLIANCE FOR EUROPE, University Hospital Heidelberg, Imperial College Healthcare NHS Trust, Alfried Krupp Krankenhaus, University Hospital, Bordeaux | Atrial Fibrillation, Intracerebral Hemorrhage | 05/24 | 05/24 | | |
RIVACAST, NCT06195540: RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing |
|
|
| Not yet recruiting | 3 | 1424 | Europe | Rivaroxaban 10 MG, Low Heparin Molecular Weight | University Hospital, Angers | Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism, Lower Limb Trauma, Thromboprophylaxis, Immobilisation | 08/26 | 08/26 | | |
NCT05033314: THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) |
|
|
| Recruiting | 3 | 50 | Canada | Rivaroxaban 10 MG, Xarelto 10mg, Placebo | Kevin H.M. Kuo, MD, MSc, FRCPC | Sickle Cell Disease, Central Venous Catheter Thrombosis, Venous Thromboembolism | 06/24 | 12/24 | | |
| Not yet recruiting | 3 | 1084 | NA | Direct-Acting Oral Anticoagulants (used as per local standard practice), Apixaban, Dabigatran Etexilate Mesilate, Edoxaban, Rivaroxaban | Walton Centre NHS Foundation Trust, University of Liverpool, National Institute for Health Research, United Kingdom | Traumatic Intracranial Haemorrhage | 12/27 | 07/28 | | |
VALERIA, NCT04999176: Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin |
|
|
| Recruiting | 3 | 440 | RoW | Rivaroxaban, Xarelto, Enoxaparin, Clexane | André Luiz Malavasi Longo de Oliveira, Science Valley Research Institute | Cancer, Rivaroxaban, Venous Thromboembolism, Thromboprophylaxis | 07/24 | 07/24 | | |
EPICT, NCT04066764: Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters |
|
|
| Recruiting | 3 | 200 | RoW | Rivaroxaban, Xarelto, Warfarin, coumadin, Nadroparin, Fraxiparin | Second Affiliated Hospital, School of Medicine, Zhejiang University, Sir Run Run Shaw Hospital, Huadong Hospital, Shanghai Zhongshan Hospital, Shanghai 5th People's Hospital, Yantai Yuhuangding Hospital, Anhui Provincial Hospital | Venous Thromboembolism | 10/24 | 10/24 | | |
| Recruiting | 3 | 700 | US | Rivaroxaban | Mayo Clinic, Ottawa Heart Institute Research Corporation | Radial Artery Occlusion | 12/24 | 12/24 | | |
PLICTS, NCT04067505: Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The Study |
|
|
| Recruiting | 3 | 224 | RoW | Rivaroxaban, Xarelto, Warfarin, coumadin, Nadroparin, Fraxiparin | Second Affiliated Hospital, School of Medicine, Zhejiang University, Sir Run Run Shaw Hospital, Huadong Hospital, Shanghai Zhongshan Hospital, Shanghai 5th People's Hospital, Yantai Yuhuangding Hospital, Anhui Provincial Hospital, Zhejiang Provincial People's Hospital, Zhejiang Hospital | May-Thurner Syndrome | 12/24 | 12/24 | | |
| Recruiting | 3 | 5400 | Canada | Rivaroxaban 10 MG and acetylsalicylic acid 81 mg, Xarelto 10mg and aspirin 81mg, acetylsalicylic acid 81 mg, aspirin 81mg | Sudeep Shivakumar, Canadian Institutes of Health Research (CIHR), Nova Scotia Health Authority, Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network | Venous Thromboembolism | 12/25 | 04/26 | | |
NCT05718531: Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens. |
|
|
| Not yet recruiting | 3 | 200 | NA | Rivaroxaban 2.5 Mg Oral Tablet twice daily, Clopidogrel 75 Mg Oral Tablet, Aspirin tablet 75 mg | Assiut University | Coronary Artery Ectasia | 02/25 | 08/25 | | |
| Not yet recruiting | 3 | 250 | Canada | Rivaroxaban 10mg, Rivaroxaban, acetylsalicylic acid (ASA) 81mg Oral Tablet, Aspirin | University of Calgary, Canadian Institutes of Health Research (CIHR) | Hip Fractures | 03/25 | 03/26 | | |
| Recruiting | 3 | 1800 | Canada | Rivaroxaban 15 MG Oral Tablet [Xarelto], Xarelto | Ottawa Heart Institute Research Corporation | Radial Artery Occlusion | 12/25 | 06/26 | | |
TRACK, NCT03969953: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease |
|
|
| Recruiting | 3 | 2000 | Europe, Canada, RoW | Rivaroxaban 2.5 Mg Oral Tablet, Xarelto, Placebo | The George Institute, George Clinical Pty Ltd, Bayer, Centre Hospitalier Régional Universitaire de Nancy, King Abdullah International Medical Research Center | Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease | 06/27 | 12/27 | | |
|
| Recruiting | 3 | 360 | Europe | Acetylsalicylic acid, B01A C06, Apixaban, B01A F02, Rivaroxaban, B01A F01, Edoxaban, B01A F03 | Oslo University Hospital, University of Oslo | Aortic Stenosis | 11/26 | 11/26 | | |
BRAIN-AF, NCT02387229: Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF |
|
|
| Terminated | 3 | 1238 | Canada | Rivaroxaban, Xarelto, standard of care | Montreal Heart Institute, Canadian Stroke Prevention Intervention Network, The Montreal Health Innovations Coordinating Center (MHICC), Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma, Montreal Heart Institute Foundation, Canadian Institutes of Health Research (CIHR), Hewitt Foundation | ATRIAL FIBRILLATION | 05/24 | 05/24 | | |
| Recruiting | 3 | 1828 | Canada | Rivaroxaban 10 MG, Placebo | Ottawa Hospital Research Institute | Venous Thromboembolism, Cancer | 12/26 | 12/27 | | |
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis |
|
|
| Recruiting | 3 | 1683 | US | Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management | University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca | Intracranial Arteriosclerosis, Stroke | 05/27 | 05/27 | | |
DANCE, NCT04284839: The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial |
|
|
| Recruiting | 3 | 3500 | Canada | DOAC, Apixaban, Dabigatran, Edoxaban, Rivaroxaban, VKA, Warfarin | Population Health Research Institute, Hamilton Health Sciences Corporation | Bleeding Post Cardiac Surgery, Indication for Anticoagulation | 06/27 | 06/27 | | |
AVAJAK, NCT05198960: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms |
|
|
| Recruiting | 3 | 1308 | Europe | Direct Oral Anticoagulants, Low-dose aspirin | University Hospital, Brest | Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F, High-risk Patients | 07/27 | 07/27 | | |
2018-001735-49: RIvaroxaban for Stroke patients with AntiPhospholipid Syndrome |
|
|
| Not yet recruiting | 2/3 | 140 | Europe | Rivaroxaban, Warfarin Sodium, Film-coated tablet, Tablet, Rivaroxaban, Warfarin Sodium | University College London, Versus Arthritis (formerly Arthritis Research UK) | Patients with stroke or other ischaemic brain injury who have antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE), Patients with APS (an immune system disorder causing blood clots), with/without lupus, with ischaemic stroke (occurring when blood flow to an area of brain is cut off) or other ischaemic brain injury, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT02829957: RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding |
|
|
| Completed | 2/3 | 19 | US | Apixaban, Eliquis, Rivaroxaban, Xarelto | Indiana University | Venous Thromboembolism, Menstruation | 02/20 | 02/20 | | |
| Recruiting | 2/3 | 500 | Europe | Chloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care, Rivaroxaban, Thromboprophylaxis, Candesartan, non-RAS blocking antihypertensives, Remdesivir, Asunercept 400mg, Asunercept 100mg, Asunercept 25mg, Pentaglobin | Medical University of Vienna, Kaiser Franz Josef Hospital, SMZ-Ost Donauspital, Otto Wagner Hospital, Hospital Hietzing, Wilhelminenspital Vienna, Medical University Innsbruck, Medical University of Graz, Kepler University Hospital | COVID-19 | 12/21 | 03/22 | | |
| Completed | 2/3 | 8 | Canada | Rivaroxaban 2.5 MG [Xarelto], Placebo | University of Alberta | Type II Myocardial Infarction | 05/22 | 01/23 | | |
| Completed | 2/3 | 42 | RoW | Rivaroxaban 2.5 Mg Oral Tablet, Axabin 2.5, Rivaroxaban placebo tablets, Placebo | Mazandaran University of Medical Sciences | Stroke, Prevention | 04/23 | 04/23 | | |
| Active, not recruiting | 2/3 | 57 | Canada | Rivaroxaban, Xarelto, ASA, aspirin | Lawson Health Research Institute, The Ottawa Hospital, Dalhousie University, Niagara Health System, Hamilton Health Sciences Corporation | Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II, Multiple Myeloma Stage I, Multiple Myeloma With Failed Remission, Multiple Myeloma Stage III | 12/23 | 09/24 | | |
AA-ICAS, NCT05700266: Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis |
|
|
| Not yet recruiting | 2/3 | 1180 | NA | Rivaroxaban, Clopidogrel, Aspirin, Risk Factor Management in both arms | The First Affiliated Hospital with Nanjing Medical University, National Natural Science Foundation of China | Ischemic Stroke, Intracranial Atherosclerosis, Stenosis | 12/24 | 12/24 | | |
| Not yet recruiting | 2/3 | 120 | NA | Rivaroxaban 10 MG, Xarelto, Placebo control | Ottawa Hospital Research Institute, Canadian Institutes of Health Research (CIHR), Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Kidney Cancer Research Network of Canada | Venous Thromboembolism, Urologic Cancer | 02/26 | 02/26 | | |
| Recruiting | 2 | 600 | | | South East Sydney and Illawarra Area Health Service , Thrombosis and Haemostasis Society of Australia and New Zealand | Cancer-associated thrombosis, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism | | | | |
4445a: A Phase 2 study evaluating andexanet alfa and XARELTO® (rivaroxaban) |
|
|
| Ongoing | 2 | 0 | RoW | andexanet alfa (PRT4445) | Portola | Healthy volunteers | | | | |
|
|
| Ongoing | 2 | 81 | Europe | Rivaroxaban 20mg, N/A, Film-coated tablet | Manchester University NHS Foundation Trust, NIHR Clinical Scientist Award | Breast Cancer, Breast Cancer, Diseases [C] - Cancer [C04] | | | | |
2012-002345-38: Comparison of rivaroxaban (Xarelto®; Bayer HealthCare), fixed-dose oral anticoagulant (blood thinner), versus warfarin in patients with antiphospholipid syndrome (called APS), with or without \'lupus\' (systemic lupus erythematosus) |
|
|
| Ongoing | 2 | 156 | Europe | Rivaroxaban, Warfarin, Xarelto, The generic name is warfarin and many producers will be involved, Xarelto, The generic name is warfarin and many producers will be involved | University College London, Arthritis Research UK, Bayer plc | Patients with antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE). | | | | |
2016-003240-37: Study to evaluate the effect of rivaroxaban in patients with advanced liver disease with portal vein thrombosis Estudio para evaluar el efecto del rivaroxaban en pacientes con enfermedad hepática en fase avanzada con trombosis portal |
|
|
| Ongoing | 2 | 134 | Europe | Film-coated tablet, Xarelto® | Fundación para la Investigación Biomédica Hospital Ramón y Cajal, Carlos III Health Institute (National Health System) | Liver cirrhosis and portal vein thrombosis Cirrosis hepática y trombosis de la vena porta, Liver disease in advanced stage, with the possibility of developing portal vein thrombosis (occlusion of the vein that carries blood to the liver) Enfermedad hepática en fase avanzada, con posibilidad de desarrollar trombosis en la vena porta (oclusión de la vena que lleva la sangre al hÃgado), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2017-001567-20: Assessment of Dual antiplatelet therapy versus Rivaroxaban In atrial Fibrillation patients Treated with left atrial appendage closure: The randomized ADRIFT Study Evaluation de la double antiagrégation plaquettaire versus Rivaroxaban dans les suites de la fermeture d'auricule pour les patients souffrant de fibrillation atriale : Etude randomisée ADRIFT |
|
|
| Not yet recruiting | 2 | 90 | Europe | Xarelto 10mg, Xarelto 15 mg, Kardegic, Plavix 75 mg, Tablet, Powder for oral solution, Xarelto 10mg, Xarelto 15 mg, Kardegic, Plavix 75 mg | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | patients souffrant de fibrillation atriale non valvulaire et ayant subi une fermeture d'auricule gauche, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2019-001723-12: Aspirin® plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis in patients with post-thrombotic syndrome (long-term condition associated with redness, swelling, leg pain, and ulcers as a results of deep vein thrombosis) |
|
|
| Not yet recruiting | 2 | 316 | Europe | Aspirin protect 100 mg, Film-coated tablet, Aspirin protect 100 mg | Universitätsspital Zürich, Klinik für Angiologie, Universitätsspital Zürich, Klinik für Angiologie, Bayer (Schweiz) AG, BARD Medica S.A. | Post-thrombotic syndrome, Post-thrombotic syndrome is a long-term complication of a deep vein thrombosis. It may include following symptoms: pain, swelling, itching , red/brown skin discoloration and ulcer at the affected leg., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-004507-13: A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is comapred to another drug called Rivaroxaban in patients with heart condition that causes an irregular and abnormally fast heart rate. |
|
|
| Not yet recruiting | 2 | 1200 | Europe, RoW | Abelacimab, Xarelto 15mg film-coated tablets, Xarelto 20mg film-coated tablets, MAA868, Concentrate for solution for injection, Film-coated tablet, Xarelto 15mg film-coated tablets, Xarelto 20mg film-coated tablets | Anthos Therapeutics, Anthos Therapeutics | Atrial Fibrillation, A heart condition that causes an irregular and abnormally fast heart rate., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR2000031649: A prospective, randomized, controlled study of rivaroxaban in the prevention of venous thrombosis in patients with deep vein catheterization chemotherapy for breast cancer |
|
|
| Completed | 2 | 200 | | rivaroxaban 10mg.po.qd ;Without preventive anticoagulant | Beijing Chaoyang District San Huan Cancer Hospital; Beijing Chaoyang District San Huan Cancer Hospital, Apply for funds from chaoyang district science and technology commission | Venous thrombosis of breast cancer | | | | |
2020-002282-33: Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT) |
|
|
| Not yet recruiting | 2 | 400 | Europe | Xarelto, Film-coated tablet, Solution for injection, Solution for injection in pre-filled syringe, Xarelto | Charité - Universitaetsmedizin Berlin, Bayer AG, DZHK - Deutsches Zentrum für Herz-Kreislauf-Forschung | Patients with moderate to severe COVID-19 disease which may cause acute cardiac injury, Patients with moderate to severe COVID-19 disease which may cause acute cardiac injury, Diseases [C] - Virus Diseases [C02] | | | | |
2021-005788-34: Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal defect Plaatjesremming versus directe antistollingsmedicatie bij patiënten die sluiting van een patent foramen ovale of atriaal septum defect ondergaan |
|
|
| Ongoing | 2 | 52 | Europe | Tablet, Plavix, Acetylsalicylylzuur Cardio (and others), Xarelto | St. Antonius Hospital, St. Antonius Onderzoeksfonds | Atrial septal defect or patent foramen ovale indicated for percutaneous closure with an occluder device. Atriaal septum defect of patent foramen ovale met een indicatie om percutaan te sluiten met een implantaat, Atrial septal defect or patent foramen ovale indicated for percutaneous closure with an occluder device. Atriaal septum defect of patent foramen ovale met een indicatie om via de lies (percutaan) te sluiten met een implantaat, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ECRU, NCT05088928: Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care |
|
|
| Not yet recruiting | 2 | 40 | RoW | Apixaban, ECRU Tablets, Rivaroxaban, Rivascot tablets | Scotmann Pharmaceuticals, Rawalpindi Medical College | COVID-19 | 05/22 | 08/22 | | |
NCT05006287: The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery |
|
|
| Active, not recruiting | 2 | 100 | Canada | Non-vitamin K oral anticoagulants (NOACs), Apixaban, Dabigatran, Edoxaban, Rivaroxaban, Warfarin | St. Paul's Hospital, Canada | Atrial Fibrillation | 05/24 | 05/24 | | |
| Withdrawn | 2 | 206 | NA | Warfarin, Coumadin, Dabigatran, Pradaxa, Rivaroxaban, Xarelto, Apixaban, Eliquis, Edoxaban, Lixiana | Laval University | Anticoagulant-induced Bleeding | 01/23 | 03/23 | | |
| Recruiting | 2 | 60 | RoW | Rivaroxaban 15 MG, Clopidogrel 75mg, Acetylsalicylic acid 100mg, Aspirin, Clopidogrel 75 Mg Oral Tablet, Plavix | Instituto Nacional de Cardiologia Ignacio Chavez | Acute Coronary Syndrome, Coronary Artery Ectasia | 06/23 | 07/24 | | |
ARIVA, NCT04128956: Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS |
|
|
| Terminated | 2 | 172 | Europe | Aspirin 100mg, Aspirin | University of Zurich, University Hospital Heidelberg, Medical University of Vienna, RWTH Aachen University, Klinikum Arnsberg, University Hospital Freiburg | Venous Thromboses, Stent Stenosis | 02/24 | 02/24 | | |
| Active, not recruiting | 2 | 1200 | Europe, Canada, US, RoW | Abelacimab, MAA868, Rivaroxaban | Anthos Therapeutics, Inc., The TIMI Study Group, Fortrea | Atrial Fibrillation (AF), Stroke | 12/23 | 12/25 | | |
|
NCT04593784: Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults |
|
|
| Recruiting | 2 | 108 | US | Ciraparantag, PER977, AMAG 977, Placebo, PBO, Point-of-Care Coagulometer (investigational device), Coagulometer | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | Healthy | 12/23 | 12/23 | | |
| Completed | 2 | 272 | Europe | Rivaroxaban 10 MG Oral Tablet [Xarelto] | Insel Gruppe AG, University Hospital Bern, Bayer, Janssen Pharmaceuticals | Bariatric Surgery | 12/23 | 12/23 | | |
NCT06220123: A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery |
|
|
| Not yet recruiting | 2 | 350 | NA | SHR-2004, Enoxaparin Sodium Injection; Rivaroxaban Tablets | Beijing Suncadia Pharmaceuticals Co., Ltd | Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery | 06/25 | 07/25 | | |
| Active, not recruiting | 2 | 43 | Europe | Rivaroxaban, Warfarin | University College, London, University College London Hospitals, Barking, Havering and Redbridge University Hospitals NHS Trust, Hammersmith Hospitals NHS Trust, Epsom and St Helier University Hospitals NHS Trust, Barts & The London NHS Trust, King's College Hospital NHS Trust, Versus Arthritis (Funder) | Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Stroke, Ischemic Stroke, Brain Ischemia | 02/25 | 08/25 | | |
